Literature DB >> 16022901

The identification of immunodominant linear epitopes of dengue type 2 virus capsid and NS4a proteins using pin-bound peptides.

Ravulapalli Anandarao1, Sathyamangalam Swaminathan, Navin Khanna.   

Abstract

We have used multi-pin peptide synthesis strategy to identify B-cell epitopes on two small dengue virus proteins, capsid and NS4a. We have identified several linear, immunodominant epitopes on both these proteins. Almost all these epitopes mapped to regions predicted to be hydrophilic based on Kyte and Doolittle profiles. Of the capsid epitopes identified in this study, the most immunogenic ones mapped to the C-terminal alpha4 helix, which lies on the solvent-exposed surface of the capsid dimer. The capsid epitopes were dengue-specific in that they could recognize antibodies in dengue virus-, but not yellow fever virus (YFV)- or Japanese encephalitis virus (JEV)-immune sera. This study has demonstrated the presence of anti-NS4a antibodies in dengue-patient sera definitively, for the first time, using authentic NS4a-derived pin-bound peptides as capture antigens. All the NS4a epitopes mapped to the amino-terminal third of the NS4a molecule. Our study suggests that the immunodominant epitopes of these two dengue proteins might have the potential to be used as a part of a recombinant multi-epitope protein containing carefully chosen E and NS1 epitopes for the detection of dengue infections with a high degree of sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16022901     DOI: 10.1016/j.virusres.2005.03.022

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  8 in total

1.  Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM.

Authors:  Yayan Luo; Xiaolan Guo; Huijun Yan; Danyun Fang; Gucheng Zeng; Junmei Zhou; Lifang Jiang
Journal:  Appl Microbiol Biotechnol       Date:  2015-03-31       Impact factor: 4.813

2.  Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population.

Authors:  Hapuarachchige Chanditha Hapuarachchi; Rachel Choon Rong Chua; Yuan Shi; Tun Lin Thein; Linda Kay Lee; Kim Sung Lee; David Chien Lye; Lee Ching Ng; Yee Sin Leo
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

3.  Natural antibody responses to the capsid protein in sera of Dengue infected patients from Sri Lanka.

Authors:  Mahesha N Nadugala; Chandima Jeewandara; Gathsaurie N Malavige; Prasad H Premaratne; Charitha L Goonasekara
Journal:  PLoS One       Date:  2017-06-05       Impact factor: 3.240

4.  Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles.

Authors:  Yanqi Chan; Seyed Davoud Jazayeri; Babu Ramanathan; Chit Laa Poh
Journal:  Vaccines (Basel)       Date:  2020-07-25

5.  Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3).

Authors:  Andréa N M Rangel da Silva; Eduardo J M Nascimento; Marli Tenório Cordeiro; Laura H V G Gil; Frederico G C Abath; Silvia M L Montenegro; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

6.  Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.

Authors:  Ya-Yan Luo; Jun-Jie Feng; Jun-Mei Zhou; Zhi-Zhun Yu; Dan-Yun Fang; Hui-Jun Yan; Gu-Cheng Zeng; Li-Fang Jiang
Journal:  BMC Microbiol       Date:  2013-08-29       Impact factor: 3.605

7.  Identification of linear human B-cell epitopes of tick-borne encephalitis virus.

Authors:  Suvi Kuivanen; Jussi Hepojoki; Sirkka Vene; Antti Vaheri; Olli Vapalahti
Journal:  Virol J       Date:  2014-06-19       Impact factor: 4.099

8.  Screening and identification of B-cell epitopes within envelope protein of tembusu virus.

Authors:  Dongmin Zhao; Kaikai Han; Xinmei Huang; Lijiao Zhang; Huili Wang; Na Liu; Yujie Tian; Qingtao Liu; Jing Yang; Yuzhuo Liu; Yin Li
Journal:  Virol J       Date:  2018-09-17       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.